Anaemia management in non-dialysis chronic kidney disease: Flexibility of target to target stability?

Nephron - Clinical Practice

Volumn 114, Issue 4, 2010, Pages

  De Nicola, Luca ^a   Minutolo, Roberto ^a   Conte, Giuseppe ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Anaemia; Chronic kidney disease; End stage renal disease; Epoetin; Haemoglobin variability

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOXIA; IRON THERAPY; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; SHORT SURVEY; SURVIVAL;

ANEMIA; ANIMALS; DISEASE MANAGEMENT; DRUG DELIVERY SYSTEMS; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 74249116167     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000276574     Document Type: Short Survey

References (34)

1. Locatelli F, Covic A, Eckardt KU, Wiecek A, Vanholder R, ERA-EDTA ERBP Advisory Board: Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009; 24: 348-354.
2. KDOQI: KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease, 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50: 471-530.
3. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098. (Pubitemid 44749317)
4. Mohandas N, Kim YR, Tycko DH, Orlik J, Wyatt J, Groner W: Accurate and independent measurement of volume and hemoglobin concentration of individual red cells by light scattering. Blood 1986; 68: 506-513. (Pubitemid 16050676)
5. Rosenblit J, Abreu CR, Szterling LN, Kutner JM, Hamerschlak N, Frutuoso P, Paiva TR, Ferreira OC Jr: Evaluation of three methods for hemoglobin measurement in a blood donor setting. Sao Paulo Med J 1999; 117: 108-112.
6. Kalantar-Zadeh K, Aronoff GR: Hemoglobin variability in anemia of chronic kidney disease. J Am Soc Nephrol 2009; 20: 479-487.
7. De Nicola L, Conte G, Chiodini P, Cianciaruso B, Pota A, Bellizzi V, Tirino G, Avino D, Catapano F, Minutolo R: Stability of target hemoglobin levels during the first year of epoetin treatment in CKD patients. Clin J Am Soc Nephrol 2007; 2: 938-946.
8. Boudville N, Djurdjev O, Macdougall I, de Francisco AL, Deray G, Besarab A, Stevens PE, Walker RG, Ureña P, Iñigo P, Minutolo R, Haviv YS, Yeates K, Agüera ML, MacRae JM, Levin A: Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality. Clin J Am Soc Nephrol 2009; 4: 1176-1182.
9. Minutolo R, Chiodini P, Cianciaruso B, Pota A, Bellizzi V, Avino D, Mascia S, Laurino S, Bertino V, Conte G, De Nicola L: Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 552-559.
10. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047. (Pubitemid 350074801)
11. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J: Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002; 162: 1401-1408. (Pubitemid 34655201)
12. De Nicola L, Minutolo R, Chiodini P, Zamboli P, Zoccali C, Castellino P, Donadio C, Strippoli M, Casino F, Giannattasio M, Petrarulo F, Virgilio M, Laraia E, Di Iorio BR, Savica V, Conte G, Target Blood Pressure Levels in Chronic Kidney Disease (TABLE in CKD) Study Group: Global approach to cardiovascular risk in chronic kidney disease: reality and opportunities for intervention. Kidney Int 2006; 69: 538-545. (Pubitemid 43164447)
13. Locatelli F, Pisoni RL, Akizawa T, Cruz JM, DeOreo PB, Lameire NH, Held PJ: Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/ DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings. Am J Kidney Dis 2004; 44:S27-S33. (Pubitemid 39369938)
14. Collins AJ, Brenner RM, Ofman JJ, Chi EM, Stuccio-White N, Krishnan M, Solid C, Ofsthun NJ, Lazarus JM: Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 2005; 46: 481-488. (Pubitemid 41208184)
15. Ross DW, Ayscue LH, Watson J, Bentley SA: Stability of hematologic parameters in healthy subjects. Intraindividual versus inter- individual variation. Am J Clin Pathol 1988; 90: 262-267.
16. Dot D, Mirò J, Fuentes-Arderiu X: Withinsubject biological variation of hematological quantities and analytical goals. Arch Pathol Lab Med 1992; 116: 825-826.
17. Goodnough LT, Bach RG: Anemia, transfusion, and mortality. N Engl J Med 2001; 345: 1272-1273.
18. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P: Anemia and mortality in heart failure patients: a systematic review and meta-analysis. J Am Coll Cardiol 2008; 52: 818-827. (Pubitemid 351881986)
19. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW, American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050-1065.
20. Hyre AD, Fox CS, Astor BC, Cohen AJ, Muntner P: The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment. Am J Kidney Dis 2006; 49: 37-45. (Pubitemid 44932194)
21. Pereg D, Tirosh A, Shochat T, Hasdai D; Metabolic, Lifestyle and Nutrition Assessment in Young Adults (MELANY) Investigators: Mild renal dysfunction associated with incident coronary artery disease in young males. Eur Heart J 2008; 29: 198-203.
22. Nangaku M: Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006; 17: 17-25. (Pubitemid 39274273)
23. Fine LG, Norman JT: Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 2008; 74: 867-872.
24. Bellizzi V, Minutolo R, Terracciano V, Iodice C, Giannattasio P, De Nicola L, Conte G, Di Iorio BR: Influence of the cyclic variation of hydration status on hemoglobin levels in hemodialysis patients. Am J Kidney Dis 2002; 40: 549-555. (Pubitemid 34971284)
25. Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI: Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007; 18: 3164-3170. (Pubitemid 350223976)
26. Lacombe C, Mayeux P: Biology of erythropoietin. Haematologica 1998; 83: 724-732. (Pubitemid 28492155)
27. Weiss MJ, dos Santos CO: Chaperoning erythropoiesis. Blood 2009; 113: 2136-2144.
28. Fishbane S: Iron management in nondialysis- dependent CKD. Am J Kidney Dis 2007; 49: 736-743. (Pubitemid 46802932)
29. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB: Hepcidin - a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1015-1016.
30. Dallalio G, Law E, Means RT Jr: Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood 2006; 107: 2702-2704.
31. Zoccali C, Abramowicz D, Cannata-Andia JB, Cochat P, Covic A, Eckardt KU, Fouque D, Heimburger O, McLeod A, Lindley E, Locatelli F, Spasovski G, Tattersall J, Van Biesen W, Wanner C, Vanholder R, European Best Practice Guidelines, European Renal Best Practice: European best practice quo vadis? From European Best Practice Guidelines (EBPG) to European Renal Best Practice (ERBP). Nephrol Dial Transplant 2008; 23: 2162-2166.
32. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK: Secondary analysis of the CHOIR trial epoetin- alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74: 791-798.
33. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; the TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-2032.
34. Shaneyfelt TM, Centor RM: Reassessment of clinical practice guidelines: go gently into that good night. JAMA 2009; 301: 868-869.